Roche reports positive five-year survival outcomes for extensive-stage small cell lung cancer

small cell lung cancer roche
IMbrella A, an extension of the Phase III IMpower133 study, demonstrates the potential for a durable overall survival benefit with Tecentriq plus chemotherapy in extensive-stage small cell lung cancer (ES-SCLC)
IMbrella A data build on the previously reported IMpower133 trial, which was the first clinically meaningful advance in the treatment of ES-SCLC in more than twenty years

Log In or Register as a healthcare professional to read the full article.

Share via

Also worth reading

People also read:

Hansel E. Ybañez USAID Field operations Tuberculosis
Tuberculosis a Major Threat in the Philippines, Fight Assisted by USAID

The Philippines, grappling with an alarming TB burden, has witnessed a stark 37 percent decline in TB case notifications in 2020 due to the pandemic. However, the U.S. Agency for International Development (USAID) is stepping in with crucial support, launching a dedicated TB Recovery Plan to bolster the National TB Program’s efforts in combating this scourge. We also spoke with Dr. Hansel E. Ybañez, field operations manager for USAID.

Read More »